on behalf of the cardia investigators - dr. yahya kiwan cardia investigators • principal...
TRANSCRIPT
![Page 1: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/1.jpg)
Dr Akhil Kapur London Chest Hospital, Barts and the London NHS Trust, London, UK
On behalf of the CARDia Investigators
![Page 2: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/2.jpg)
2
Revascularisation in Diabetic Patients with Multivessel Disease
• CABG generally considered superior to PCI• 1996 presentation of the BARI diabetic subset (353
patients)• At 5 years angioplasty had double the mortality of
patients receiving surgery • No specific randomised comparison of CABG and PCI
until now• Largest randomised comparison to date• The CARDia Trial compared a strategy of optimal PCI
with up to date CABG
![Page 3: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/3.jpg)
3
CARDia Investigators
• Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt
• Sponsored by Hammersmith Hospitals NHS Trust • Study Management Group : Akhil Kapur, Roger Hall,
Marcus Flather• Steering Committee : Roger Hall, Akhil Kapur, Kevin Beatt,
Marcus Flather, Iqbal Malik, Petros Nihoyannopoulos, Keith Oldroyd, Andreas Baumbach, Gianni Angelini, Jon Anderson, Mark de Belder, Adam de Belder
• Critical Event Committee: Iqbal Malik, Prakash Punjabi, Kevin Fox, Simon Corbett, Doug Fraser, Andrew Archbold, Simon Kennon, Tim Gilbert, Iain Simpson, Mark Gunning, Tony Page
![Page 4: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/4.jpg)
4
CARDia InvestigatorsCARDia Investigators
• DSMB : Desmond Julian, Tom Treasure, Adrian Banning• Coordinating Centres and Data management: Clinical Trials
and Evaluation Unit, Royal Brompton Hospital, London –Director Marcus Flather, Fiona Nugara, Claire Foley, Nicola Delahunty, Katie Qureshi, Jean Booth ; HH NHS Trust – Marie Claire Rickard, Claire Sheehy, Marie Leahy, Jeremy Butts
• Statisticians: Michael Roughton, Konrad Jamrozik, Judith Cooper
• Supported by major grants from Eli Lilly, Cordis, BMS/Sanofi, Hammersmith Hospitals special trustees,
• Further support from Boston Scientific, Medtronic, Guidant and Jomed
![Page 5: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/5.jpg)
5
CARDiaParticipating Centres
Centre Local investigator Patients Recruited
Hammersmith Hospital, London Kevin Beatt, Punit Ramrakha 84St Mary’s Hospital, London Iqbal Malik 62London Chest Hospital Martin Rothman, Akhil Kapur 52St James Hospital, Dublin Peter Crean 42Royal Sussex County, Brighton Steve Holmberg, Adam de Belder 34Bristol Royal Infirmary Andreas Baumbach, Gianni
Angelini33
James Cook University Hosp, Middlesboro Mark de Belder 32Western Infirmary, Glasgow Keith Oldroyd 30King’s College Hospital Martyn Thomas 27Manchester Royal infirmary Fath Ordoubadi 19Hairmyres Hospital Keith Oldroyd, Barry Vallance 13St Thomas’ Hospital Simon Redwood, Graham Venn 12
![Page 6: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/6.jpg)
6
CARDiaParticipating Centres continued
Centre Local investigator Patients recruited
City Hospital, Birmingham Teri Millane 12Royal Victoria, Blackpool David Roberts 11Beaumont, Dublin David Foley 11St Bartholomew’s Hospital, London Richard Schilling, Akhil Kapur 10Papworth Hospital, Cambridge Peter Schofield 8Royal Brompton Hospital Carlo di Mario 4
North Staffs, Stoke Mark Gunning 4
City Hospital, Nottingham Kamran Baig, Rob Henderson 3
CTC, Liverpool Rod Stables 3
Northern General, Sheffield Ever Grech 2
Harefield Hospital Charles Ilsley 1Mayday, Surrey Kevin Beatt 1
![Page 7: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/7.jpg)
7
CARDia Trial Hypothesis
In diabetic patients with multivessel disease amenable to both CABG or PCI
Optimal PCI is not inferior to up-to-date CABG
![Page 8: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/8.jpg)
8
CARDia Trial DesignDiabetic patients with multivessel disease
or complex single vessel disease
Suitable for PCI or CABG
Inclusion and exclusioncriteria met
CONSENT
Randomisation
Up to date CABG Optimal PCI stent +abciximab
DES 71% BMS 29%
![Page 9: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/9.jpg)
9
Main Exclusion Criteria
• Informed consent could not be obtained• Age >80 years• Previous CABG or PCI• Left main stem disease• Cardiogenic shock• Recent ST elevation myocardial infarction• Contraindications to abciximab, aspirin and clopidogrel
![Page 10: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/10.jpg)
10
Trial Design contd
• CABG historically assumed to be superior to PCI (based on BARI
subset)
• Investigator Initiated Trial designed to show non inferiority of PCI
• Sample size of 600 patients based on ARTS and EPI trials • and the hypothesis (test of non-inferiority) to be tested is:
• Ho: pe > 1.3ps (10 EP in PCI group >1.3 times to 10 EP in the CABG group)
• Ha: pe < 1.3 ps (10 EP in PCI group <1.3 times to 10 EP in the CABG group)
• 510 patients recruited from Jan 2002 to May 2007Early termination due to slowing recruitment but follow up extended to 5 years
![Page 11: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/11.jpg)
11
Primary endpoint:• Composite event rate at 1 year of death/non-fatal MI/non-
fatal stroke (time to first event)Major secondary: • Further revascularisation at 1 yearSecondary• Severe bleeding complications at 30 days• New requirement for permanent dialysis• Neurological morbidity• Quality of life • Cost difference between treatments• Change in LV function
Endpoints
![Page 12: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/12.jpg)
12
Definitions of primary outcomes
• Death: All cause mortality• Non fatal MI :
• First 7 days post revascularisation one or more of following –• CK or CKMB >3x ULN, Tn (T or I ) >1, ECG new q waves
• After first 7 days – at least 2 of following –• raised enzymes (CK/CKMB >x2 ULN or Troponin Tor I
>1), new q waves on ECG, clinical evidence of ischaemicsymptoms
• Non Fatal Stroke :• Neurological signs/symptoms that persist for more than 24
hrs with a neurological imaging study that does not indicate a different aetiology
![Page 13: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/13.jpg)
13
CARDia Patient flow Chart
254 patients8=withdrew consent
1=data not yet available
510 Pts randomised
CABG PCI
96% (245) in 1 year follow up 98% (251) in 1 year follow up
229=received CABG1=died
11=cross over to PCI
256 patients2=withdrew consent
2 data not yet available
252=received PCI1=cross over to CABG
![Page 14: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/14.jpg)
14
Baseline Clinical Characteristics
4.94.3Other
2.52.1Black
25.918.8South Asian
0.26466.774.8White
%Ethnicity
0.31883.384.8kgWeight
0.386168.6169.4cmHeight
0.38668.769.8Beats/minHeart rate
0.68373.673.2mmhgDiastolic blood pressure
0.766136.7137.3 mmHgSystolic Blood pressure
0.06870.777.8%Male
0.49464.363.7YearsAge256254Number in group
p valuePCICABGUnitsVariable
![Page 15: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/15.jpg)
15
Baseline Clinical Characteristics
p valuePCICABGUnitsVariable
63.363.6Non-smoker
%Smoking Status
0.75210.010.3YrsYears with Diabetes
30.669.4
31.468.6
Insulin treatedNon Insulin treated
%Diabetes Status
78.576.3Elective
0.54721.523.7Acute
%Admission Type
![Page 16: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/16.jpg)
16
Baseline Clinical Characteristicsp valuePCICABGUnitsVariable
0.60159.160.0%EF
0.84155.458.7Normal or Good
%LV function
0.637104.2106.9Creatinine
0.5997.97.9%Hba1c
0.5211.413.3%Cerebrovascular disease history
0.283.55.6%Chronic lung disease history
0.9319.49.6%Peripheral vascular disease history
0.4375.54.0%Renal failure
0.03292.987.2%Hyperlipidaemia history
0.26376.480.5%Hypertension history
0.13164.858.3%3 vessel disease
![Page 17: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/17.jpg)
17
Procedural details
1(1,4)9 (7,16)493median days (interquartile
range)
Time in hospital
37 (13,59)64 (27,110)493median days(interquartile
range)
Time from randomisation to index procedure
PCICABGValid nunits
![Page 18: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/18.jpg)
18
PCI procedural detailsUse prior to procedure of:
• aspirin - 100%• clopidogrel - 94%• abciximab - 95%
---------------------------------------------------------------------------------• 3 vessel disease - 65%• 3 vessels treated in these patients - 88%---------------------------------------------------------------------------------• average no. of stents per patient - 3.5• average stent length - 71mm---------------------------------------------------------------------------------• DES patients (cypher) - 71% (180)• BMS patients - 29% (72)
![Page 19: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/19.jpg)
19
CABG procedural details
• 3 vessel disease - 58%• 3 vessels treated in these patients - 90%
----------------------------------------------------------------------------
• average no of grafts - 2.8• LIMAs - 89%• % with at least two arterial grafts - 17%• % off pump - 31%
![Page 20: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/20.jpg)
20
Results – adjudicated events – intention to treat analysis
5.31(2.00,14.11)
0.0019.9% (25)2.0% (5)Further revascularisation
1.72(1.02,2.87)
0.0417.5%11.0%Composite outcome of death, MI, stroke, repeat revasc at 1 year
1.15(0.65,2.03)
0.6311.6% (29)10.2% (25)Death, MI and stroke at one year –primary outcome
0.16(0.02,1.33)
0.090.4% (1)2.5% (6)Non fatal stroke
1.51(0.75,3.03)
0.258.4% (21)5.7% (14)Non fatal MI
0.98 (0.36,2.64)
0.833.2% (8)3.3 % (8)Death
OR and 95% CI
p valuePCI(251)
CABG(245)
Adjudicated events post randomisation
![Page 21: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/21.jpg)
21
Primary composite outcome at 1 year
p =0.63
Death, non fatal MI, non fatal stroke
p =0.63
![Page 22: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/22.jpg)
22
1 2 3
Individual 1 year outcomes Individual 1 year outcomes
3.2 %3.2 %(n=8)(n=8)
DeathDeath
p=0.83 p=0.34 p=0.09
Non fatal MINon fatal MI
3.3 %3.3 %(n=8)(n=8)
5.7%5.7%(n=14)(n=14)
8.4%8.4%(n=21)(n=21)
2.5%2.5%(n=6)(n=6)
0.4%0.4%(n=1)(n=1)
Non fatal strokeNon fatal stroke
CABG (n=245)
PCI (n=251)
![Page 23: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/23.jpg)
23
Survival at 1 year CABG vs PCI
p=0.83p=0.83
![Page 24: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/24.jpg)
24
Death, MI, stroke and repeat revascularisation
p=0.04p=0.04
![Page 25: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/25.jpg)
25
Subgroup - CABG vs PCI-DES
0.0137.3%2.0%Further revascularisation at 1 year
0.9810.1%10.2%Composite outcome of death, non fatal MI and non fatal stroke at one year – primary outcome
0.0410%2.5%Non fatal stroke
0.21715.1%11.0%Composite outcome of death, non fatal MI, non fatal stroke and repeat revasc at 1 year
0.8526.2%5.7%Non fatal MI
0.7233.9%3.3%Death
p valueCABG vs DES
PCI (DES)n=179
CABGn=245
Comparison of CABG vs DES in PCI group
![Page 26: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/26.jpg)
26
Subgroup - CABG vs PCI-DES Composite endpoint at 1 year
Death, non fatal MI, non fatal stroke
p=0.98
![Page 27: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/27.jpg)
27
Study Limitations
• Planned recruitment not achieved 510 patients out of 600 recruited – 85%
• Formal non-inferiority parameters not fulfilled (insufficient power)
• These are preliminary results – a few events are still to be adjudicated
![Page 28: On behalf of the CARDia Investigators - Dr. Yahya Kiwan CARDia Investigators • Principal Investigators: Akhil Kapur, Roger Hall, Kevin Beatt • Sponsored by Hammersmith Hospitals](https://reader030.vdocuments.us/reader030/viewer/2022021516/5b1ce49f7f8b9aad5d8b99bc/html5/thumbnails/28.jpg)
28
CARDia: Main Conclusions
• No apparent difference between PCI and CABG at one year in:• Death • Composite of Death, MI and stroke
• More repeat revascularisation in the PCI group
• PCI may now be considered a reasonable strategy in diabetic patients with multivessel disease
• Longer follow up is needed